Sejal Saglani1, Stephen Lui2, Nicola Ullmann1, Gaynor A Campbell2, Rebekah T Sherburn2, Sara A Mathie2, Laura Denney2, Cara J Bossley3, Timothy Oates2, Simone A Walker2, Andrew Bush3, Clare M Lloyd4. 1. Leukocyte Biology Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom; Respiratory Paediatrics, Royal Brompton Hospital, and National Heart & Lung Institute, Imperial College London, London, United Kingdom. 2. Leukocyte Biology Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom. 3. Respiratory Paediatrics, Royal Brompton Hospital, and National Heart & Lung Institute, Imperial College London, London, United Kingdom. 4. Leukocyte Biology Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address: c.lloyd@imperial.ac.uk.
Abstract
BACKGROUND: TH2 cytokines are not responsible for the ongoing symptoms and pathology in children with severe therapy-resistant asthma (STRA). IL-33 induces airway hyperresponsiveness, but its role in airway remodeling and steroid resistance is unknown. OBJECTIVE: We sought to investigate the relationship between IL-33 and airway remodeling in pediatric patients with STRA. METHODS: IL-33 levels were quantified in neonatal mice given inhaled house dust mite (HDM), and the effect of blocking IL-13 on remodeling and IL-33 levels was assessed. HDM-induced allergic airways disease (AAD) in neonatal ST2(-/-) mice lacking the IL-33 receptor was assessed, together with collagen production after IL-33 administration. The effect of steroid therapy on IL-33 levels in patients with neonatal AAD was explored. IL-33 expression was quantified in endobronchial biopsy (EB) specimens from children with STRA and related to remodeling, and collagen production by airway fibroblasts from pediatric patients stimulated with IL-33 and budesonide was quantified. RESULTS: Blocking IL-13 after AAD was established in neonatal mice and did not reduce remodeling or IL-33 levels; airway hyperresponsiveness was only partially reduced. IL-33 promoted collagen synthesis both from asthmatic fibroblasts from pediatric patients and after intranasal administration in mice. Increased cellular expression of IL-33, but not IL-13, was associated with increased reticular basement membrane thickness in EB specimens from children with STRA, whereas remodeling was absent in HDM-exposed ST2(-/-) mice. IL-33 levels were maintained, whereas IL-13 levels were abrogated by steroid treatment in neonatal HDM-exposed mice and in EB specimens from children with STRA. CONCLUSION: IL-33 is a relatively steroid-resistant mediator that promotes airway remodeling in patients with STRA and is an important therapeutic target.
BACKGROUND: TH2 cytokines are not responsible for the ongoing symptoms and pathology in children with severe therapy-resistant asthma (STRA). IL-33 induces airway hyperresponsiveness, but its role in airway remodeling and steroid resistance is unknown. OBJECTIVE: We sought to investigate the relationship between IL-33 and airway remodeling in pediatric patients with STRA. METHODS: IL-33 levels were quantified in neonatal mice given inhaled house dust mite (HDM), and the effect of blocking IL-13 on remodeling and IL-33 levels was assessed. HDM-induced allergic airways disease (AAD) in neonatal ST2(-/-) mice lacking the IL-33 receptor was assessed, together with collagen production after IL-33 administration. The effect of steroid therapy on IL-33 levels in patients with neonatal AAD was explored. IL-33 expression was quantified in endobronchial biopsy (EB) specimens from children with STRA and related to remodeling, and collagen production by airway fibroblasts from pediatric patients stimulated with IL-33 and budesonide was quantified. RESULTS: Blocking IL-13 after AAD was established in neonatal mice and did not reduce remodeling or IL-33 levels; airway hyperresponsiveness was only partially reduced. IL-33 promoted collagen synthesis both from asthmatic fibroblasts from pediatric patients and after intranasal administration in mice. Increased cellular expression of IL-33, but not IL-13, was associated with increased reticular basement membrane thickness in EB specimens from children with STRA, whereas remodeling was absent in HDM-exposed ST2(-/-) mice. IL-33 levels were maintained, whereas IL-13 levels were abrogated by steroid treatment in neonatal HDM-exposed mice and in EB specimens from children with STRA. CONCLUSION: IL-33 is a relatively steroid-resistant mediator that promotes airway remodeling in patients with STRA and is an important therapeutic target.
Authors: Jonathan Corren; Robert F Lemanske; Nicola A Hanania; Phillip E Korenblat; Merdad V Parsey; Joseph R Arron; Jeffrey M Harris; Heleen Scheerens; Lawren C Wu; Zheng Su; Sofia Mosesova; Mark D Eisner; Sean P Bohen; John G Matthews Journal: N Engl J Med Date: 2011-08-03 Impact factor: 91.245
Authors: Stanley J Szefler; Robert S Zeiger; Tmirah Haselkorn; David R Mink; Tripthi V Kamath; James E Fish; Bradley E Chipps Journal: Ann Allergy Asthma Immunol Date: 2011-06-02 Impact factor: 6.347
Authors: Ya-Jen Chang; Hye Young Kim; Lee A Albacker; Nicole Baumgarth; Andrew N J McKenzie; Dirk E Smith; Rosemarie H Dekruyff; Dale T Umetsu Journal: Nat Immunol Date: 2011-05-29 Impact factor: 25.606
Authors: Nicolas Regamey; Matthias Ochs; Tom N Hilliard; Christian Mühlfeld; Nikki Cornish; Louise Fleming; Sejal Saglani; Eric W F W Alton; Andrew Bush; Peter K Jeffery; Jane C Davies Journal: Am J Respir Crit Care Med Date: 2008-01-24 Impact factor: 21.405
Authors: Sejal Saglani; Donald N Payne; Jie Zhu; Zhuo Wang; Andrew G Nicholson; Andrew Bush; Peter K Jeffery Journal: Am J Respir Crit Care Med Date: 2007-08-16 Impact factor: 21.405
Authors: Sejal Saglani; Sara A Mathie; Lisa G Gregory; Matthew J Bell; Andrew Bush; Clare M Lloyd Journal: Am J Respir Cell Mol Biol Date: 2009-01-16 Impact factor: 6.914
Authors: Irene H Heijink; Henk F Kauffman; Edo Vellenga; Christa A Veltman-Starkenburg; Dirkje S Postma; Jan G R de Monchy Journal: Int Arch Allergy Immunol Date: 2007-09-10 Impact factor: 2.749
Authors: Gang Liu; Marion A Cooley; Andrew G Jarnicki; Alan C-Y Hsu; Prema M Nair; Tatt Jhong Haw; Michael Fricker; Shaan L Gellatly; Richard Y Kim; Mark D Inman; Gavin Tjin; Peter A B Wark; Marjorie M Walker; Jay C Horvat; Brian G Oliver; W Scott Argraves; Darryl A Knight; Janette K Burgess; Philip M Hansbro Journal: JCI Insight Date: 2016-06-16
Authors: Erin D Gordon; Laura J Simpson; Cydney L Rios; Lando Ringel; Marrah E Lachowicz-Scroggins; Michael C Peters; Agata Wesolowska-Andersen; Jeanmarie R Gonzalez; Hannah J MacLeod; Laura S Christian; Shaopeng Yuan; Liam Barry; Prescott G Woodruff; K Mark Ansel; Karl Nocka; Max A Seibold; John V Fahy Journal: Proc Natl Acad Sci U S A Date: 2016-07-18 Impact factor: 11.205
Authors: Kohei Hasegawa; Jonathan M Mansbach; Yury A Bochkov; James E Gern; Pedro A Piedra; Cindy S Bauer; Stephen J Teach; Susan Wu; Ashley F Sullivan; Carlos A Camargo Journal: JAMA Pediatr Date: 2019-06-01 Impact factor: 16.193
Authors: Anne M Fitzpatrick; Susan T Stephenson; Milton R Brown; Khristopher Nguyen; Shaneka Douglas; Lou Ann S Brown Journal: J Allergy Clin Immunol Pract Date: 2016-09-21
Authors: U M Zissler; A M Chaker; R Effner; M Ulrich; F Guerth; G Piontek; K Dietz; M Regn; B Knapp; F J Theis; H Heine; K Suttner; C B Schmidt-Weber Journal: Mucosal Immunol Date: 2015-11-18 Impact factor: 7.313